Provided is a means for inhibiting the function of CD69, wherein inflammatory reactions can be suppressed. Specifically, provided are: an inflammatory disease treatment composition including an antibody that specifically recognises a myosin regulatory light-chain polypeptide (hereinafter abbreviated to Myl), preferably Myl9, Myl12a, and Myl12b, and inhibits the effect of an action when Myl, and CD69 coexist an inflammatory disease treatment method including the prescription of a therapeutically effective amount of the antibody to a subject diagnosed as having an inflammatory disease and a method for identification of a compound which inhibits the effect of the action when Myl, and CD69 coexist, and an inflammatory disease treatment candidate compound identification method characterised in that a compound which inhibits the effect is selected.
